LOS ANGELES, March 23, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (“CURE” or the “Company”) (OTC:CURR), an innovative drug delivery and development company, today announced that the Company will participate in an educational panel about cannabis science in Hawaii. This “Dinner & Dialogue” is put on by Lua Ola, Hawaii’s leading medical cannabis provider, and will address how to build a pharmaceutical cannabis system in the state. The panel will take place on Tuesday, March 27, in Honolulu, Hawaii.
CURE is leveraging the synergism created by combining cannabinoids and terpenes into its advanced oral thin film, CUREfilm™, a proprietary polymer and encapsulation platform. CURE’s CEO, Robert Davidson will participate on the panel in Hawaii and will discuss the company’s pharmaceutical cannabinoid projects.
“It is essential to share our knowledge and understanding on potential pharmaceutical cannabinoid drug formulations and delivery systems because many medical needs are not currently being met by traditional pharmaceuticals,” Davidson said. “This panel is made up of some of the leading minds in the field so we can work together to get FDA-approved drugs to market for those who need them.”
Joining Davidson on this panel are other industry leaders and experts in the medical cannabis industry, including:
- Tracy Ryan, CEO of CANNAKIDS & Founder of SAVINGSOPHIE.org – In addition to being a member of CURE’s advisory board, Ryan has dedicated a huge part of her life to educating herself on the medicinal powers of medical marijuana in treating her own daughter’s disease, as well as all other pediatric and adult cancers, epilepsy, autism, and beyond.
- Joshua Crossney, President & Founder of JCANNA, Inc. – Crossney is working to bridge the gap between analytical sciences and the medical cannabis industry to help improve the quality of medicinal cannabis products being used by patients.
- Autumn Karcey, President of Cultivo Inc. – Karcey became passionate about creating optimal indoor environments where plants can be grown in a healthy, stable manner, free of pests and pathogens without the use of harmful pesticides and chemicals.
- Dr. Dedi Meiri from Israel Institute of Technology of Cancer Biology and Cannabinoid Research – Dr. Meiri heads the "Laboratory of Cancer Biology and Cannabinoid Research" at the Technion Israel Institute of Technology. His lab investigates the therapeutic potential of Phyto cannabinoids with focus on the antitumor effects of cannabinoids. CURE is sponsoring research in Dr. Meiri’s lab to understand how varying cannabinoid compounds within cannabis strains can affect various cancer subtypes. The results of the research will be used to predict how to match a cancer subtype with an effective cannabis extract in order to optimize treatment efficacy.
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system (CUREfilm™), one of the most advanced oral thin film on the market today. CURE is developing an array of products in cutting-edge delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Telephone: (413) 627-2468